Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholesterol absorption blockade with ezetimibe.

Peter P Toth1, Michael H Davidson

  • 1Director of Preventive Cardiology, Sterling Rock Falls Clinic, Illinois, University of Illnois School of Medicine, Peoria, 61081, USA. peter.toth@srfc.com

Current Drug Targets. Cardiovascular & Haematological Disorders
|March 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.

American journal of preventive cardiology·2026
Same author

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

American journal of preventive cardiology·2026
Same author

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.

European heart journal·2026
Same author

The emerging role of CETP inhibition in the prevention of Alzheimer's disease.

American journal of preventive cardiology·2026
Same author

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same author

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same journal

Non-invasive atherosclerosis imaging: use to assess response to novel or combination lipid therapies.

Current drug targets. Cardiovascular & haematological disorders·2006
Same journal

Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.

Current drug targets. Cardiovascular & haematological disorders·2006
Same journal

Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.

Current drug targets. Cardiovascular & haematological disorders·2006
Same journal

Liver x receptors: potential novel targets in cardiovascular diseases.

Current drug targets. Cardiovascular & haematological disorders·2006
Same journal

Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis.

Current drug targets. Cardiovascular & haematological disorders·2006
Same journal

Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis.

Current drug targets. Cardiovascular & haematological disorders·2006
See all related articles

Lowering atherogenic lipoproteins like LDL-C reduces cardiovascular events. Ezetimibe, a cholesterol absorption inhibitor, effectively lowers LDL-C and helps patients reach lipid goals, safely with or without statins.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Reducing atherogenic lipoproteins is crucial for patients at risk of cardiovascular events.
  • Lowering low-density lipoprotein cholesterol (LDL-C) significantly decreases mortality, stroke, and myocardial infarction.
  • Statins are primary agents for dyslipidemia but have limitations like side effects and inability to reach targets in some patients.

Purpose of the Study:

  • To introduce Ezetimibe as a novel cholesterol absorption inhibitor.
  • To evaluate Ezetimibe's efficacy and safety in managing hyperlipidemia.
  • To determine if Ezetimibe aids patients in achieving lipid-lowering goals.

Main Methods:

  • Ezetimibe inhibits cholesterol absorption in the jejunum by blocking its translocation.

Related Experiment Videos

  • Ezetimibe undergoes enterohepatic recirculation with minimal systemic exposure.
  • Ezetimibe's pharmacokinetic profile does not adversely interact with statins.

    • Main Results:

    • Ezetimibe significantly reduces serum LDL-C levels.
    • Ezetimibe is safe for monotherapy and combination use with statins.
    • Ezetimibe increases the proportion of patients achieving their lipid-lowering targets.

    Conclusions:

    • Ezetimibe is a safe and effective option for managing hyperlipidemia, familial hypercholesterolemia, and sitosterolemia.
    • Ezetimibe offers a valuable therapeutic option for patients unable to tolerate high-dose statins or achieve goals with statins alone.
    • Ezetimibe enhances the ability of patients to reach target lipid levels, contributing to cardiovascular risk reduction.